Tradestie Institutional Equity Comparison Engine

CGEN vs ACHV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while ACHV counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
CGEN 12.4x vs ACHV 35.3x Fwd P/E
Growth & Margin Winner CGEN
Op Margin 41.3% vs 0.0% ยท YoY +102.1% vs +0.0%
Momentum & Technical Winner ACHV
1Y +23.2% vs +43.0% ยท 52W Pos 33% vs 69%
Options & Structure Winner ACHV
BREAKDOWN (57th %ile IV) vs BREAKOUT (23rd %ile IV)
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEN +23.17% ACHV +43.04% Spread: +24.3 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CGEN TTM Op. Margin: 41.3% ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEN vs ACHV. Trailing 12-month operating profitability (CGEN 41.3% vs ACHV 0.0%) and valuation multiples (CGEN 12.4x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEN (6) vs ACHV (3)
Institutional Metric CGEN ACHV Criterion Row Winner
Market Capitalization Scale $193.2M $692.8M Larger Scale ACHV
Trailing P/E Ratio Valuation 5.2x 35.3x Lower Multiple CGEN
Forward P/E Ratio Valuation 12.4x 35.3x Lower Multiple CGEN
Revenue Growth (YoY) Growth +102.1% +0.0% Higher Growth CGEN
Operating Margin (TTM) Profitability 41.3% 0.0% Higher Margin CGEN
Net Profit Margin Profitability 47.9% 0.0% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency 57.2% -845.0% Higher ROE CGEN
52-Week Range Position Momentum 33% ($1โ€“$3) 69% ($3โ€“$9) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 1.44ฮฒ ยท 62% Vol 1.73ฮฒ ยท 62% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEN vs ACHV Buy Guide
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEN nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.